Jeffrey M. Holzbeierlein, M.D.

Professor
Director of Urologic Oncology
Department of Urology

M.D., University of Oklahoma, 1994
Residency, Vanderbilt University, 1994-2000
Fellowship, Memorial Sloan Kettering Cancer Center-New York, 2000-2002


jholzbeierlein@kumc.edu

Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. His research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy.

Selected Publications

Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011 Jun 1;71(8):835-45.

Holzbeierlein JM. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jan 24.

Lee EK, Baack J, Penn H, Bromfield CT, Duchene DA, Thrasher JB, Holzbeierlein  JM. Active surveillance for prostate cancer in a veteran population. Can J Urol.  2010 Dec;17(6):5429-35.

Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2010 Oct 28.

Holzbeierlein JM, Windsperger A, Vielhauer G. Hsp90: a drug target? Curr Oncol Rep. 2010 Mar;12(2):95-101.

Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate  cancer cells. Prostate. 2010 Jan 1;70(1):27-36.

Lee EK, Holzbeierlein JM. Management of the contralateral testicle in patients with unilateral testicular cancer. World J Urol. 2009 Aug;27(4):421-6.

Graham SM, Holzbeierlein JM. Adjuvant radiation therapy after radical prostatectomy: when is it indicated? Curr Urol Rep. 2009 May;10(3):194-8.

Karan D, Holzbeierlein J, Thrasher JB. Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res. 2009 Jan 1;69(1):2-5.

Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol. 2009 Feb;181(2):615-20.

Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, Blagg BS. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem. 2008 Nov 21;73(22):8901-20.

Last modified: Jun 25, 2014

Jeffrey M. Holzbeierlein, M.D.

Contact

Jeffrey M. Holzbeierlein, M.D.
Professor
Director of Urologic Oncology

ID=x1698